Ophthalmology Update - Cleveland Clinic

More documents

Recommendations

Info

i n v e s t i g a t i O n s i n t h i s s e c t i O n : 03 retina 13 cornea 22 glaucoma 23 pediatrics 27 Oncology 28 refractive surgery 30 Uveitis 32 Oculoplastics Investigations When the lines between research and patient care blur, doors open and excellence flourishes. // O p h t h a l m O l O g y U p d a t e s p e c i a l e d i t i O n 2 0 0 6
Cole Eye Researchers Aiming to Elucidate Physiological and Pathological Roles of TIMP3 Identification of the role of vascular endothelial growth factor (VEGF) in the development of choroidal neovascularization (CNV) has led to exciting advances in treatment for exudative age-related macular degeneration (AMD). However, understanding of the pathogenesis and regulation of ocular neovascularization is still very limited. at the cole eye institute, Bela anand-apte, m.B.B.s., ph.d., has been conducting research aiming to characterize the physiological role of tissue inhibitor of metalloproteinase-3 (timp3) and to elucidate the mechanisms by which it might regulate angiogenesis in eyes with amd and sorsby’s fundus dystrophy (sFd). starting off with the basic knowledge that proteolytic degradation of capillary basement membrane by matrix metalloproteinases (mmps) is an initiating event in the development of new blood vessel growth, dr. anand-apte and colleagues focused their attention on the timps that inhibit mmp function. their interest was directed to timp3 because in contrast to other members of the timp family, timp3 uniquely binds to extracellular matrix. While these studies were under way, independent researchers linked mutations in the timp3 gene to sFd. “although timp3 is ubiquitous throughout the body, patients with sFd have only ocular symptoms. therefore, it made sense that as a bound protein, timp3 would have a localized effect,” dr. anandapte explains. experiments conducted so far in a mouse model of laser-induced cnv show that timp3 is a potent inhibitor of angiogenesis. additional studies indicate that its mechanism appears to involve inhibition of vegF action by preventing vegF from binding to its receptors. Ongoing studies are examining what effect timp3 might have on the progenitor cells that are known to be involved in the development of cnv in the mouse model. the researchers are also aiming to understand the role of the mutated timp3 in sFd with the hope that information generated will provide clues to its participation in amd-related cnv pathogenesis. preliminary results from functional studies show that the mutated protein does not inhibit angiogenesis like the wild-type timp3, reports dr. anand-apte. experiments are also under way to investigate whether timp3 could be used therapeutically to prevent cnv. “Knowing that timp3 inhibits vegF, we are interested in determining if it has efficacy in regulating vegF-mediated pathological angiogenesis,” dr. anand-apte says. initial studies are being performed with intravitreal delivery of timp-3, but in the future, other modes of administration will be examined, including subcutaneous and scleral injections as well as intravitreal delivery using a controlled-release system. i n v e s t i g a t i O n s For more information, contact Bela Anand-Apte, M.B.B.S., Ph.D., at anandab@ccf.org. c O l e e y e i n s t i t U t e c l e v e l a n d c l i n i c . O r g / e y e //
Page 1 and 2: Cleveland Clinic Cole Eye Institute
Page 3: i n v e s t i g a t i O n s Dear Co
Page 7 and 8: useful prognostic tools and (2) the
Page 9 and 10: Studies on Redox-Sensitive Retinal
Page 11 and 12: Diverse Spectrum of New and Investi
Page 13 and 14: CSNB Mouse Models Provide Valuable
Page 15 and 16: Study Conclusively Links Haze After
Page 17 and 18: Corneal Biomechanical Clues Studied
Page 19 and 20: Autologous Serum Eyedrops May Offer
Page 21 and 22: Switching from ECCE to Phacoemulsif
Page 23 and 24: lens. that technique has also been
Page 25 and 26: NEI-Sponsored Study Evaluating Role
Page 27 and 28: Case Study: Five-Month-Old Boy Pres
Page 29 and 30: Study Investigates Risk Factors for
Page 31 and 32: however, a few months later she ret
Page 33 and 34: each trial will enroll 189 adult pa
Page 35 and 36: Briefly, after everting the eyelid,
Page 37 and 38: Who We Are at the cole eye institut
Page 39 and 40: Refractive Surgery FREEInG pATIEnTs
Page 41 and 42: Cole Eye Institute Staff Hilel Lewi
Page 43 and 44: Allen S. Roth, M.D. Comprehensive O
Page 45 and 46: International Ophthalmology Reviewe
Page 47 and 48: Heed Ophthalmic Foundation Executiv
Page 49 and 50: Training the Leaders of Tomorrow e
Page 51 and 52: Continuing Medical Education e d U
Page 53 and 54: Innovations in Ophthalmology los Ca
Page 55 and 56:
description/Objectives: This course
Page 57 and 58:
e d U c a t i O n a n d t r a i n i
Page 59 and 60:
Distinguished Lecture Series e d U
Page 61 and 62:
Research We will never stop pursuin
Page 63 and 64:
AMD Initiative for Prevention and C
Page 65 and 66:
A 3-Year, phase 3, multicenter, mas
Page 67 and 68:
Traboulsi EI. The challenges and su
Page 69 and 70:
Nakata K, Crabb JW, Hollyfield JG.
Page 71 and 72:
Journal of neuroscience Bjartmar L,
Page 73 and 74:
Singh AD. Ophthalmic oncology - pre
Page 75:
Netto MV, Ambrosio R, Jr., Wilson S
Page 78:
MKT 05-EYE-036
show all

Ophthalmology Update - Cleveland Clinic

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?